CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Popular weight-loss drugs like Ozempic and Zepbound have revolutionized how we tackle obesity. But now, emerging reports ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Agency will require a Limitation of Use section in the prescribing information of all extended-release ADHD stimulants ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug ...

Johnna Byrd began taking Zepbound to help her finish the weight loss journey she started. She never imagined it would help ...